Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute

SAN JOSE, Calif. (Reuters) - A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.

http://ift.tt/1RpqBkr

from Reuters: Health News
via animenewspro